T Lymphocyte News and Research

RSS

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Testosterone may impede immunity

Decreasing testosterone boosts immunity because testosterone helps control T-lymphocytes, the attack cells of the immune system, according to Mayo Clinic-led research in laboratory animals.

8 Nov 2004

Researchers uncover how HIV causes abnormalities in antibody-producing cells

HIV wreaks much of its damage by targeting the “orchestra conductor” of the immune system, a key class of T cells—CD4+ T cells—whose destructive relationship with HIV has been well-studied by AIDS researchers.

8 Sep 2004

Generic tritherapy can be used as a basic treatment for AIDS

A clinical trial, conducted in Cameroon by IRD researchers working with other organizations and supported by the ANRS, has demonstrated that one of the most common combinations currently deployed in Africa, using nevirapine, stavudine and lamivudine, satisfies these criteria.

5 Sep 2004

Epimmune presents SIV vaccine study data showing control of virus despite the presence of viral mutations

Epimmune today presented preliminary data from its ongoing SIV rhesus macaque vaccine study at the AIDS Vaccine 2004 conference in Lausanne, Switzerland.

31 Aug 2004

Genmab's HuMax-CD4 receives U.S. orphan drug designation

Genmab has announced that HuMax-CD4 for the treatment of Mycosis Fungoides (MF), which constitutes 75% of all Cutaneous T-cell Lymphomas (CTCL), has been designated an orphan drug by the US Food and Drug Administration (FDA). The US prevalence of MF is estimated at 16,000 to 20,000.

23 Aug 2004

Novel disease mechanism underlying rheumatoid arthritis

Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.

23 Aug 2004

Protein loss plays role in acute T-cell leukemia

The loss of a key protein (Smad3) in a pathway that helps prevent tumors from forming is specific to one form of childhood leukemia, but not to other pediatric and adult forms of leukemia, according to a new study published in the August 5, 2004, New England Journal of Medicine.

5 Aug 2004

Research that directs cancer-killing immune cells against the deadliest brain tumors shows promise

Researchers seeking to direct cancer-killing immune cells against the deadliest brain tumors have three new targets that show promise in laboratory studies and in a Phase I patient trial, according to two articles in the July 15 issue of the journal Cancer Research.

15 Jul 2004

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources.

3 Jul 2004

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

One of the strategies adopted consists in utilizing combinations of fixed doses of generic antiretrovirals, involving three medicinal drugs of two different classes in the same tablet.

2 Jul 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

Geneticists determine the lack of chromosomes

A healthy person’s genome contains 46 chromosomes, but an individual cell can contain less. Contemporary methods allow to determine the value of losses rather accurately. The Tomsk researchers’ effort has been supported by the Russian Foundation for Basic Research.

15 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Possible breakthrough in AIDS and cancer research

Mayo Clinic researchers have found a way to revive immunity in mice that have abnormal or deficient immune systems. The discovery may lead to a means of restoring immunity to individuals with immunodeficiency diseases such as AIDS and cancer.

20 Apr 2004

Jefferson scientists learn how HIV causes dementia

Ever since the AIDS epidemic began more than two decades ago, scientists have been trying to understand why as many as one-quarter of those infected with HIV develop dementia.

19 Apr 2004

First North American sales of Raycell X-ray blood irradiator

The Indiana Blood Center in Indianapolis, Indiana, and SMDC Laboratory in Duluth, Minnesota have both chosen to purchase MDS Nordion's Raycell(TM) blood irradiator as a means of eliminating delays in receiving irradiated blood and blood products from external suppliers and improving the service they provide to physicians and patients.

30 Mar 2004